To protect patients, visitors and health care workers, we have implemented the following procedures:
- Non-urgent medical appointments should be rescheduled or converted to telehealth visits.
- Any patient checking in must tell staff and ask for a mask if they have: A fever, cold symptoms (cough, sore throat, runny nose, shortness of breath); Flu symptoms (fever, chills, body aches, etc.).
- Anyone under 16 years of age NOT being seen as a patient is restricted from visiting any area.
- Visitor restrictions are in place. Please call to inquire about exceptions.
For general information, please visit the Colorado COVID-19 website
Thank you for doing your part to help keep everyone as safe and healthy as possible.
Brandon McMahon, MD
Associate Professor, Medicine-Hematology
Internal Medicine - Hematology and Oncology
Dr. McMahon completed his undergraduate training at Boston College, where he received a Bachelor’s degree in Chemistry with honors. He graduated AOA with his M.D. from SUNY-Upstate Medical University at Syracuse, and then moved to the University of Rochester where he completed his internal medicine residency, followed by a chief residency. He remained that the University of Rochester for his hematology fellowship, which was completed in 2007, and during which he completed the American Society of Hematology Clinical Research Training Institute.
He joined the faculty at Northwestern University in Chicago as an Assistant Professor and later Associate Professor of Medicine, where he was heavily involved in clinical operations in hematology, clinical research in thrombotic disorders and MPN, and education, receiving multiple teaching awards and serving as the associate and later director of the Hematology/Oncology fellowship program. He joined the faculty at the University of Colorado in 2016, and will be focusing on thrombosis & MPN in the clinical arena, while remaining active in fellow & resident education.
Dr. McMahon’s research involves evaluating mechanisms of thrombotic and bleeding complications in various cancers (particularly MPN), critical evaluation of common medical practices in hematology that lack significant evidence basis, and clinical trials evaluating new therapeutic developments in MPN. He has written many peer-reviewed papers on these topics, several book chapters, and edited a recently published textbook on myeloproliferative neoplasms.